Results 21 to 30 of about 41,600 (260)
Journal of Clinical Medicine, 2022 Dipeptidyl peptidase 4 (DPP-4) is a novel adipokine and may be involved in the association between adipose tissue and metabolic syndrome. We investigated DPP-4 and adiponectin levels in the serum, subcutaneous adipose tissue (SAT), and epicardial adipose tissue (EAT), and their relationship with preoperative factors, as well as comparing the DPP-4 ...
Ikuko Shibasaki +15 more
openaire +2 more sources
Metabolism Open, 2021 COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 and has become an urgent economic and health challenge. Dipeptidyl peptidase 4 (DPP4), also mentioned as a cluster of differentiation 26 (CD26) is a serine exopeptidase found in two ...
Zemene Demelash Kifle +2 more
doaj +1 more source
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors [PDF]
Diabetes & Metabolism Journal, 2022 Background It is not known which type 2 diabetes mellitus (T2DM) patients would most benefit from dipeptidyl peptidase-4 (DPP-4) inhibitor treatment.
Sangmo Hong +3 more
doaj +1 more source
DPP4 (dipeptidyl-peptidase 4) [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2013 Review on DPP4 (dipeptidyl-peptidase 4), with data on DNA, on the protein encoded, and where the gene is implicated.
Ohnuma, K, Morimoto, C
openaire +2 more sources
Journal of Diabetes Investigation, 2020 Japan's guidelines emphasize tailored therapy, but do not guide physicians on the use of a specific regimen in drug‐naive patients. The role of long‐term initial therapy could be important in key elements of diabetes treatment, such as continuation of ...
Takeshi Horii +3 more
doaj +1 more source
The role of dipeptidyl peptidase-4 inhibitors
BMJ, 2012 Will be clearer once ongoing trials are complete Type 2 diabetes is a progressive disease and greater treatment intensity is needed over time to control increasingly abnormal glucose concentrations.1 In the linked article (doi:10.1136/bmj.e1369), Karagiannis and colleagues present a systematic review and meta-analysis of the risks and benefits ...
Lasserson, D, Mant, J
openaire +4 more sources
The role of Dipeptidyl Peptidase‐4 in cutaneous disease [PDF]
Experimental Dermatology, 2020 AbstractDipeptidyl peptidase‐4 (DPP4) is a multifunctional, transmembrane glycoprotein present on the cell surface of various tissues. It is present in multiple molecular forms including cell surface and soluble. The role of DPP4 and its inhibition in cutaneous dermatoses have been a recent point of investigation.
Payal M. Patel +3 more
openaire +2 more sources
The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation [PDF]
Current Opinion in Hematology, 2013 Dipeptidyl peptidase 4 (DPP4, CD26) is a protease that cleaves selected amino acids at the N-terminal penultimate position and has the potential to alter the protein function. The regulation and roles of DPP4 activity are not well understood; therefore, the purpose of this review is to discuss the recent literature regarding DPP4 regulation, as well as
Heather, O'Leary +2 more
openaire +2 more sources
SAGE Open Medicine, 2016 Objective: This updated meta-analysis determines the effect of dipeptidyl peptidase-4 inhibitors on glycemic and tolerability outcomes in patients with type 2 diabetes mellitus and chronic kidney disease with glomerular filtration rate of ⩽60 mL/min or ...
Devada Singh-Franco +2 more
doaj +1 more source
The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors [PDF]
BioMed Research International, 2014 A cell surface serine protease, dipeptidyl peptidase 4 (DPP-4), cleaves dipeptide from peptides containing proline or alanine in the N-terminal penultimate position. Two important incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), enhance meal-stimulated insulin secretion from pancreaticβ-cells, but ...
Kim, Na-Hyung, Yu, Taeyang, Lee, Dae Ho
openaire +2 more sources